Zougla.gr#Biogen #νωτιαία_μυϊκή_ατροφία Νωτιαία μυϊκή ατροφία: Νέα δεδομένα για το nusinersen https://www.zougla.gr/ygeia/farmako-nea/notiaia-myiki-atrofia-nea-dedomena-gia-to-nusinersen/?utm_source=dlvr.it&utm_medium=mastodon
Thế Giới Trong Tầm TayTin vui cho bệnh nhân ALS! Biogen đã triển khai Tofersen, liệu pháp nhắm trực tiếp vào gen SOD1 tại Trung Quốc, mở ra hy vọng mới trong điều trị. Mũi tiêm đầu tiên đã được thực hiện tại Bệnh viện Tam Hiệp, đánh dấu bước tiến quan trọng. #ALS #Tofersen #GenTherapy #Biogen #Yhoc https://ift.tt/XcnHhtD
Phương pháp điều trị gen ALS đột phá được triển khai tại Trung Quốc - Thế Giới Trong Tầm Tay
Biogen triển khai Tofersen tại Trung Quốc, loại thuốc nhắm mục tiêu gen đầu tiên dành cho ALS do đột biến SOD1, đánh dấu đột phá trong điều trị.
Tech Cybersecurity NieuwsSage therapeutics verwerpt overnamebod van biogen ter waarde van $469 miljoen https://www.trendingtech.news/trending-news/2025/01/51116/sage-therapeutics-verwerpt-overnamebod-van-biogen-ter-waarde-van-469-miljoen #Sage Therapeutics #Biogen #overnamebod #biotechnologie #aandeelhouders #Trending #News #Nieuws
Fda keurt maandelijkse dosis leqembi goed voor alzheimerpatiënten https://www.trendingtech.news/trending-news/2025/01/51047/fda-keurt-maandelijkse-dosis-leqembi-goed-voor-alzheimerpati-nten #FDA #Alzheimer #Leqembi #Eisai #Biogen #Trending #News #Nieuws
ExTraders GlobalZimmer Biomet ($ZBH) reported EPS of $1.74, matching the forecast of $1.74. Revenue was $1.82B, slightly exceeding the expected $1.8B.
Global Payments ($GPN) achieved EPS of $3.08, just below the forecast of $3.09. Revenue reached $2.6B, surpassing the anticipated $2.38B.
Biogen ($BIIB) posted EPS of $4.08, exceeding the forecast of $3.77. Revenue was $2.47B, slightly above the expected $2.43B.
#Earnings #Q3 #ZimmerBiomet #GlobalPayments #Biogen #Investing #Finance #Stocks #MarketNews
The Japan TimesTwo new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
Biogen $BIIB: Q2 EPS of $5.28 beat the forecast of $4.01. Revenue was $2.47B vs. $2.39B expected. #Biogen
Iron Mountain $IRM: Q2 EPS matched the forecast at $0.42. Revenue was $1.53B vs. $1.5B expected. #IronMountain #Earnings #Stocks
EURACTIV HealthEuropean Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
cafepharmaModerna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B—Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset —9 top biopharma CEO-to-employee pay gaps --http://bit.ly/w28kSd #biogen #mergersandacquisitions #boehringeringelheim #cardiovasculardisease #pharmaceos #executivecompensation #paygap #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma